

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 37/36	A1	(11) International Publication Number: WO 92/03154 (43) International Publication Date: 5 March 1992 (05.03.92)
(21) International Application Number: PCT/SE91/00557 (22) International Filing Date: 22 August 1991 (22.08.91) (30) Priority data: 90027.149 24 August 1990 (24.08.90) SE (71) Applicant (for all designated States except US): KABI PHARMACIA AB [SE/SE]; S-751 82 Uppsala (SE). (72) Inventors; and (75) Inventors/Applicants (for US only) : FRYKLUND, Linda [SE/SE]; Solängsvägen 106, S-191 54 Sollentuna (SE). GLUCKMAN, Peter [NZ/NZ]; 78 Lucerne Road, Remuera, Auckland 5 (NZ). SKOTTNER, Anna [SE/SE]; Lobovägen 3, S-178 00 Ekerö (SE).	(74) Agents: TANNERFELDT, Agneta et al.; Kabi Pharmacia AB, S-112 87 Stockholm (SE). (81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), GR (European patent), HU, IT (European patent), JP, LU (European patent), NL (European patent), NO, SE (European patent), US. Published <i>With international search report.</i>	
(54) Title: PRODUCT AND USE OF IT FOR THE TREATMENT OF CATABOLIC STATES COMPRISING AUTHENTIC IGF-1 AND HYPOCALORIC AMOUNT OF NUTRITIENTS (57) Abstract A method and a product for the treatment or prevention of a catabolic state in a patient where the patient is treated with authentic IGF-1 and a hypocaloric amount of nutrient, for example intravenously.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU ⁺	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE ⁺	Germany	MC	Monaco	US	United States of America
DK	Denmark				

⁺ Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

PRODUCT AND USE OF IT FOR THE TREATMENT OF CATABOLIC
STATES COMPRISING AUTHENTIC IGF-1 AND HYPOCALORIC
AMOUNT OF NUTRIENTS

This invention relates to a method and a product for the treatment or prevention of the catabolic state in patients, involving the administration of insulin-like growth factor 1 (IGF-1).

IGF-1 is a peptide belonging to the somatomedin family . It is comprised of 70 amino acids, including 3 disulphide bonds. Its amino acid sequence is known. IGF-1 is normally found in the circulation bound to at least two different classes of binding proteins (ca 150.000 D) and the low molecular weight binding protein (ca 30.000 D). IGF-1 is mitogenic in cell lines (i.e in vitro) and has been shown to stimulate growth in growth hormone (GH) deficient animals.

The IGF-1 concentration is in plasma (blood), at least partly, regulated by GH but also by other hormones, such as thyroxine, and by the nutritional status.

A wide variety of clinical conditions can lead to loss of weight and muscle in patients and in particular to protein depletion. Examples of possible causes are burns, multiple trauma, sepsis, major surgery and malignant tumours. In some cases, patients cannot be fed orally at all (e.g in the case of gastrointestinal surgery) or only at an inadequate caloric level. In other instances nutrients taken orally cannot be absorbed or cannot be absorbed with normal efficiency via the gastro-intestinal tract. In such cases intravenous feeding must be utilised but it is difficult or sometimes impossible to supply normal caloric requirements by the intravenous route. There is also a risk for liquid overload.

In such circumstances there is a need to be able to treat or prevent a catabolic state whilst supplying the patient with a diet that, to the

extent that it is utilised by the body, is inadequate to meet his/her normal caloric requirements. Such a diet is referred to herein as a "hypocaloric diet".

It has been suggested (International Patent Application WO 87/04074) that protein accretion or nitrogen retention can be promoted in the case of a hypocaloric diet by the administration of growth hormone (GH). It is thought that any beneficial effect resulting from the administration of GH may be derived from an increased level of IGF-1 in the bloodstream that has been observed in some cases. On the other hand, there is conflicting evidence both from human and ovine studies where administration of GH did not bring about any IGF-1 response. In any event, not all classes of patients are able to respond to the administration of GH by an increase in IGF-1 levels. Indeed, relative GH resistance is frequently seen in catabolic states.

Moreover, very young children particularly those less than one year of age do not have the necessary GH receptors and in severely-starved adults the GH receptor function is impaired or the receptors are reduced in number so that administration of GH in such cases is ineffective or only effective in greatly increased (i.e. pharmacological) quantities. High doses of GH are undesirable as they can lead to hyperglycaemia and in any event the drug is expensive. Furthermore, in the case of adults, it is not always easy to determine whether a given patient will be able to respond to the treatment with GH or not.

It has also been suggested that treatment with certain analogues of IGF-1 can lead to increased growth rates in animals (International Patent Application WO 87/01038, WO 89/05822). It was postulated that the use of analogues having certain amino acid residues absent from the N-terminus would reduce the degree of binding to the IGF-1 binding proteins. This was based on the assumption that only free (i.e. unbound) IGF-1 has the desired anti-catabolic activity. On the other hand, it has been suggested that freely-circulating IGF-1 may be responsible for the known

tendency of that material to cause undesirable hypoglycaemia. In fact, the prevailing opinion was that systemically administered IGF-1 could not be used therapeutically for that reason. However, we now believe that the bound forms of IGF-1 may be responsible for the desired anabolic effects.

We have found that the administration of authentic IGF-1, whether obtained by recombinant DNA or other techniques, in conjunction with a hypocaloric diet, is advantageous in the treatment of catabolic states.

Tests carried out by us on lambs which had been fasted for 48 hours and which were in negative nitrogen balance indicated that administration of IGF-1 could reduce protein catabolism at doses that did not affect carbohydrate metabolism (i.e. which are not hypoglycaemic). These tests indicated a positive effect on protein metabolism within only 120 minutes of starting an IGF-1 infusion. Thus, a positive effect was noticed much more quickly than would have been expected. Our tests indicated that the effect of IGF-1 was both to reduce protein breakdown and to stimulate protein synthesis, both in liver and the skeletal muscle. This conclusion is supported by other work carried out by us on hypophysectomized rats. The rats were supplied by infusion with 200 micrograms of rhIGF-1 daily (equals 60 micrograms IGF/kg/hour) for 7 days. The rats showed an increase in body weight without a change in food intake, indicating increased food utilization, and also a lower rate of excretion of urea, which indicates that IGF-1 can suppress protein breakdown. Again, no undesirable hypoglycaemic effects were observed.

According to one aspect of this invention, a product for the treatment or prevention of a catabolic state in a patient comprises authentic IGF-1 and a hypocaloric amount of nutrient, for simultaneous, separate, or sequential use.

The invention also includes use of authentic IGF-1 and a hypocaloric amount of nutrient in the manufacture of a product for the treatment or prevention of a catabolic state in a patient.

The invention further includes a method for the treatment or prevention of a catabolic state by administering to a patient authentic IGF-1 in conjunction with a hypocaloric diet.

By "authentic IGF-1" we mean IGF-1 having the complete amino acid sequence of natural human IGF-1. It is preferably obtained by recombinant DNA technology, e.g. from transformed yeast cells.

By "prevention of a catabolic state" we include an effect in which protein synthesis is stimulated and/or an effect in which the rate of protein degradation is decreased.

We have found that the response time (as evidenced by the onset of protein accretion) of a patient to treatment in accordance with the invention is much shorter than would have been expected from the results obtained from administration of GH in conjunction with a hypocaloric diet, even taking into account that it is known that administration of GH normally leads to an increase in the level of IGF-1. Also, a surprisingly low dose of authentic IGF-1 in conjunction with a hypocaloric diet has been found to be effective. It is advantageous to be able to administer relatively low doses of the drug in order to minimise the hypoglycaemic effect of IGF-1. Further, in the case of the critically ill patient the rapid response available by treatment with authentic IGF-1 may be essential for survival.

The nutrient may be for oral, intragastric or parenteral (especially intravenous) administration. The amount of nutrient supplied is preferably such that which is utilised by the patient provides up to 90%, and preferably up to 70%, of the resting metabolic requirement. This may, for example, be achieved by supplying to the patient up to about 60 kcal/kg of body weight per day for an adult.

The nutrient may include one or more carbohydrates (e.g. glucose) and/or lipids, and/or proteins or protein-amino acids that are found in proteins.

The dose of authentic IGF-1 is preferably 0.02 to 20 mg/kg/day, more preferably 0.05 to 2 mg/kg/day.

The IGF-1 may be for administration by intravenous infusion, possibly in combination with total parenteral nutrition (TPN). Alternatively, the IGF-1 may be for administration by other means, such as subcutaneous or intramuscular injection, orally, or nasally.

This invention has a wide range of potential applications.

In sick premature infants on parental nutrition positive nitrogen balance is difficult to achieve without fluid overload. Because of GH receptor immaturity GH will not be efficacious. Thus IGF-1 will prove useful in very low birth weight infants (e.g. <27 weeks gestation) requiring nutritional support, in neonates following surgery (particularly bowel surgery) or sepsis and in patients with gastroenteric disease (e.g. necrotising enterocolitis).

In all prepubertal children GH receptor levels are relatively low. Therefore in such children who are severely ill and in negative nitrogen balance authentic IGF-1 in conjunction with hypercaloric diet will be therapeutically advantageous. Similarly in hypothyroid individuals, relative GH resistance is likely. In such patients and in hypopituitary adults or children not receiving GH where an emergency situation arises leading to catabolism (e.g. trauma or sepsis) IGF-1 will be more effective than GH as it takes some days for GH to induce the GH-receptor and valuable therapy time will be lost. Individuals with genetic defects in the GH-receptor (e.g. Laron dwarfs, pygmies, etc.) who for other reasons require metabolic support will respond specifically to IGF-1. As under-nutrition (either hypocaloric, low protein or mixed) can lead to GH resistance either due to a loss of high affinity GH-receptors or to

postreceptor mechanisms leading to a failure to induce IGF-1 release, IGF-1 will be useful in situations such as chronic bowel disease, e.g Crohns disease, protein losing enteropathies, short gut syndromes, postgastroenteritic malabsorption states, cystic fibrosis chronic or acute pancreatitis, and hepatitis. It will also be effective in other states where only a hypocaloric diet can be given which creates a disadvantageous clinical syndrome (anorexia nervosa, bulimia, vomiting in pregnancy, etc.) GH resistance is also reported in chronic renal failure and authentic IGF-1 may be more advantageous than GH in such situations particularly because the increased feed efficiency means that muscle sparing is possible at lower net protein intakes thus reducing the load on the kidneys in terms of urea excretion. As the liver is the major source of systemic IGF-1, acute or chronic liver disease will induce GH resistance. Thus authentic IGF-1 may be particularly valuable in acute hepatic failure where protein loading can be dangerous and in catabolic states associated with chronic liver disease.

As protein loss, particularly from skeletal muscle, is detrimental in acute situations such as post surgery (where it can postpone or prolong recovery), trauma, acute renal failure due to many causes (for the reasons explained above), the rapid anabolic and anticatabolic effects of authentic IGF-1 offer a unique approach to acute therapy. As IGF-1 therapy will reduce the amount of parental nutrition needed because of its effects on feed conversion, allowing a hypocaloric diet to be supplied, fluid requirements will be less so that in situations of catabolism for any reasons with coexistent heart failure, renal failure, or severe hypertension, authentic IGF-1 will be an important therapeutic aid.

The results on tests on rats and lambs are now given by way of non-limiting examples, and with reference to the drawings (figures 1 to 6b).

Example i

A nutrient mixture was made up from the following components:

- (1) 16.88 ml of a 50% glucose solution
- (2) 4.05 ml of a 20% "Intralipid" solution
- (3) 8.34 ml of 20% "Vamin 18" solution

"Intralipid" and "Vamin" are registered trade marks. "Intralipid" is a fat emulsion and "Vamin 18" is an amino acid mixture.

Rats were supplied with a hypocaloric amount of the above nutrient mixture at a daily rate of 20-25 ml by intravenous infusion, simultaneously with a daily dose of 1 mg (equals ca 190 micrograms/kg/hour) of recombinant authentic human IGF-1. This provided a caloric intake of 95-125 kcal/kg/day. A control group of rats was infused with normal saline solution instead of the IGF-1. The effect on the rats is set out in the form of graphs in Figures 1 to 4.

The figures show that the rats were fasted for 1 day, were then supplied with TPN alone for 2 days, and then TPN together with the IGF-1 for a further 6 days. Figure 1 shows that the energy consumption by both the control group and the IGF-1 supplied group was essentially the same. However, Figure 2 indicates that, from the beginning of the infusion with IGF-1, the body weight of the IGF-1 treated group remained essentially stable, whilst that of the control group continued to fall. Figure 3 shows that, during the time of IGF-1 infusion, the amount of nitrogen (in the form of urea) excreted by the control group was significantly greater than the excreted by the animals receiving IGF-1. This indicates that the rates of protein degradation was considerably higher in the control group than in the IGF-1 supplied group. Figure 4. shows that, at the end of the experiment, the rats supplied with IGF-1 had a positive nitrogen balance (i.e they had accumulated protein) whereas the control group had a negative nitrogen balance (i.e they had lost protein).

Exemple. 2.

The following experiment was performed using cryptorchid crossbred lambs having an average weight of 16 kg and within an age range of 3 to 5 months. The lambs were fasted for 48 hours and then placed in slings. Catheters were inserted into the external jugular veins to permit infusion. One group of five animals received an eight hour TPN nutrition infusion in which the protein load was 1.6 g/kg of body weight/day (i.e the maximum absorbable protein load for a sheep). The total caloric input was 50% of a sheep's normal daily requirement and of this 80% of the calories were in the form of carbohydrate (dextrose) and 20% in the form of lipids.

After three hours of this hypocaloric parenteral nutrition administration of authentic recombinant human IGF-1 was begun. The IGF-1 was infused at the rate of 50 microgram/kg/hour for five hours. The TPN was continued at the same rate as previously. Net protein loss was determined by ^{14}C area turnover (^{14}C leucine having been incorporated into the TPN infusion).

Fig.5a shows, on the left-hand side, the basal rate of protein loss for fully-starved animals. On the right-hand side the graph shows that administration of IGF-1 alone in the rate indicated above slightly reduces the rate of protein loss (from about 3.8 to 2.8 g/kg/day) in starved lambs. Fig. 5b shows on the left -hand side that administration of TPN alone at the hypocaloric rate mentioned above reduces the rate of net protein loss to about 1g/kg/day. On the right-hand side is shown the effect of co-administration of hypocaloric TPN and IGF-1 at the rates indicated in the preceding two paragraphs.

Most surprisingly, instead of net protein loss, a net protein gain of around 0.25 gm/kg/day was observed. Thus, it has been determined that co-administration of IGF-1 with a diet providing only 50% of the normal caloric requirements (i.e the requirement for a stable condition in which protein is neither lost or gained) still leads to a significant net protein gain. Also surprising is that the effect of the combined administration of the hypocaloric TPN with the IGF-1 becomes apparent very rapidly, i.e during the five hour infusion period.

The fact that a net protein gain is achievable whilst providing only 50% of the normal caloric requirements is clinically important as it enables the total volume of the TPN and/or the protein load administered to be very substantially reduced. Volume considerations are especially important in the case of premature neonates, heart failure and renal disease. In the case of neonates in particular, TPN at conventional volume often leads to heart failure because of volume overload and the usual concomitant administration of diuretics. In the case of hepatic or renal disease it is advantageous to limit protein intake.

The fact that the effect of co-administration of IGF-1 and TPN is so rapid may be of life-saving importance in the case of critically ill patients.

Example 3

To mimic the catabolism during a septic state, TNF can be administered in animal experiments. TNF is one of many substances, released from macrophages during endotoxin septicaemia, which replicates many of the clinical and metabolic features of sepsis, eg. fever, hypotension, anorexia, hyperglycemia and a negative nitrogen balance.

Four groups of lambs were fasted for 48 hours and thereafter subjected to constant iv. infusion of ^{15}N -urea and ^6H -glucose for 480 minutes. Two groups of lambs were simultaneously given TNF (1ug/kg/h) and two groups only saline.

During the last 300 minutes IGF-1 was infused (50ug/kg/h) in one each of the pretreated groups (TNF + saline) and saline was given to the remaining two groups of lambs (TNF+ saline).

The infusion of rhIGF-1 caused a similar decrease in net protein catabolism (NPC) in lambs pretreated with TNF or saline (fig 6 a,b), whereas no significant effect was observed in the control animals given saline instead of rhIGF-1.

10

Furthermore, the effect was demonstrated to be equally rapid in both treatment groups, ie the effect of rhIGF-1 was significant already between 1 to 3 hours after the start of infusion (fig 6 a, b).

Exampel 4

The hormonal response to rhIGF-1 in the catabolic state was investigated in rats. In a rat model mimicking a trauma situation by fasting and a further food restriction (see table 1) we were able to demonstrate that rhIGF-1 significantly lowered circulating corticosterone (the active cortisone metabolite in the rat) (table 2).

Table 1

Anti-catabolic effect of IGF-1 in the food-restricted rat

100%	Fast	25 %	50 %	75 %
Nutrition	2 days	Nutrition	Nutrition	Nutrition
5 days		2 days	3 days	2 days

Treatments IGF-1 (s.c)			No of animals
1	0 microgram/day		10
2	200	"	10
3	400	"	10
4	1000	"	10

Table 2

Effects of s.c. IGF-1 injections on serum corticosterone(ng/ml)

Treatment	Basal	Post-fast nutrition	
		50 %	75 %
1 (placebo)	354	309	345
2	423	210	260
3	385	216	225 #
4	490#	183#	88#

= p<0.05 compared to placebo

This effect could be very important, since increased levels of cortisone (glucocorticoid) are the result of any stress/trauma situation. Cortisone itself affects intermediary metabolism, such as maintenance of glucose homeostasis, but is catabolic to muscle, where it decreases glucose uptake, decreases protein synthesis and increases the release of amino acids. (Basic & Clinical Endocrinology, 1983 eds Greenspan & Korsham, p 266-273).

CLAIMS

1. A product for the treatment or prevention of a catabolic state in a patient comprising authentic IGF-1 and a hypocaloric amount of nutrient for simultaneous, separate or sequential use.
2. Use of authentic IGF-1 for the preparation of a medicament for the treatment or prevention of a catabolic state in a patient in conjunction with administration to the patient of a hypocaloric amount of nutrient.
3. A method for the prevention or treatment of a catabolic state by administering to a patient authentic IGF-1 in conjunction with a hypocaloric diet.
4. A product according to Claim 1, wherein the nutrient is for oral, intragastric or parenteral administration.
5. A product according to Claim 4, wherein the nutrient is for intravenous administration.
6. A product according to any of Claims 1, 4 or 5 wherein the amount of nutrient utilised by the patient supplied is up to 90%, and preferably up to 70%, of the resting metabolic requirement.
7. A product according to any of Claims 1, 4, 5 or 6 wherein the amount of nutrient supplied to the patient amounts up to 60 kcal/kg of body weight for an adult per day.
8. A product according to Claim 1, 4, 5, 6 or 7 wherein the dose of authentic IGF-1 is 0.05 to 20 mg/kg/day, preferably 0.02 to 2 mg/kg/day.
9. A product according to Claim 1, 6, 7 or 8 wherein the authentic IGF-1 is for administration by intravenous infusion.


13

10. A product according to Claim 9 wherein the authentic IGF-1 is for administration in combination with total parenteral nutrition.

11. A product according to Claim 1, 6, 7 or 8 wherein the IGF-1 is for administration orally or nasally or by subcutaneous or intramuscular injection.

1 / 6


Figure 1



SUBSTITUTE SHEET

2 / 6


Figure 2



SUBSTITUTE SHEET

3 / 6


Figure 3



SUBSTITUTE SHEET

4 / 6

Figure 4



SUBSTITUTE SHEET

5 / 6

Figure 5a





Figure 5b



SUBSTITUTE SHEET

6 / 6

Percentage change of net protein loss during rhIGF-I infusion.

Figure 6a





Figure 6b

**SUBSTITUTE SHEET**

INTERNATIONAL SEARCH REPORT

International Application No PCT/SE 91/00557

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC5: A 61 K 37/36											
II. FIELDS SEARCHED <div style="text-align: right; margin-right: 100px;">Minimum Documentation Searched⁷</div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%; padding: 5px;">Classification System</td> <td style="padding: 5px;">Classification Symbols</td> </tr> <tr> <td style="padding: 5px;">IPC5</td> <td style="padding: 5px;">A 61 K</td> </tr> </table> <p style="font-size: small; margin-top: 5px;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in Fields Searched⁸</p> <p style="margin-top: 10px;">SE,DK,FI,NO classes as above</p>			Classification System	Classification Symbols	IPC5	A 61 K					
Classification System	Classification Symbols										
IPC5	A 61 K										
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹ <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%; padding: 5px;">Category¹⁰</th> <th style="width: 60%; padding: 5px;">Citation of Document,¹¹ with indication, where appropriate, of the relevant passages¹²</th> <th style="width: 30%; padding: 5px;">Relevant to Claim No.¹³</th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;"> Dialog Information Services, File 155, Medline 66-91/MAY, Dialog accession no. 07118481, Jiang ZM et al: "Low-dose growth hormone and hypocaloric nutrition attenuate the protein-catabolic response after major operation", Ann Surg Oct 1989, 210 (4) p 513-24 <div style="text-align: center;">--</div> </td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-11</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;"> EP, A1, 0303746 (INTERNATIONAL MINERALS AND CHEMICAL CORPORATION) 22 February 1989, see page 2, line 41 - line 54; claims 1-12 <div style="text-align: center;">--</div> <div style="text-align: center;">-----</div> </td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-11</td> </tr> </tbody> </table>			Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	X	Dialog Information Services, File 155, Medline 66-91/MAY, Dialog accession no. 07118481, Jiang ZM et al: "Low-dose growth hormone and hypocaloric nutrition attenuate the protein-catabolic response after major operation", Ann Surg Oct 1989, 210 (4) p 513-24 <div style="text-align: center;">--</div>	1-11	A	EP, A1, 0303746 (INTERNATIONAL MINERALS AND CHEMICAL CORPORATION) 22 February 1989, see page 2, line 41 - line 54; claims 1-12 <div style="text-align: center;">--</div> <div style="text-align: center;">-----</div>	1-11
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³									
X	Dialog Information Services, File 155, Medline 66-91/MAY, Dialog accession no. 07118481, Jiang ZM et al: "Low-dose growth hormone and hypocaloric nutrition attenuate the protein-catabolic response after major operation", Ann Surg Oct 1989, 210 (4) p 513-24 <div style="text-align: center;">--</div>	1-11									
A	EP, A1, 0303746 (INTERNATIONAL MINERALS AND CHEMICAL CORPORATION) 22 February 1989, see page 2, line 41 - line 54; claims 1-12 <div style="text-align: center;">--</div> <div style="text-align: center;">-----</div>	1-11									
<div style="display: flex; justify-content: space-between; font-size: x-small;"> <div> <p>* Special categories of cited documents:¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>											
IV. CERTIFICATION <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; padding: 5px;"> Date of the Actual Completion of the International Search 6th December 1991 </td> <td style="width: 50%; padding: 5px;"> Date of Mailing of this International Search Report 1991 -12- 1 0 </td> </tr> <tr> <td style="width: 50%; padding: 5px;"> International Searching Authority <div style="text-align: center; margin-top: 10px;">SWEDISH PATENT OFFICE</div> </td> <td style="width: 50%; padding: 5px;"> Signature of Authorized Officer <div style="text-align: center; margin-top: 10px;"> Anneli Jönsson </div> </td> </tr> </table>			Date of the Actual Completion of the International Search 6th December 1991	Date of Mailing of this International Search Report 1991 -12- 1 0	International Searching Authority <div style="text-align: center; margin-top: 10px;">SWEDISH PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center; margin-top: 10px;"> Anneli Jönsson </div>					
Date of the Actual Completion of the International Search 6th December 1991	Date of Mailing of this International Search Report 1991 -12- 1 0										
International Searching Authority <div style="text-align: center; margin-top: 10px;">SWEDISH PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center; margin-top: 10px;"> Anneli Jönsson </div>										

Form PCT/ISA/210 (second sheet) (January 1985)

ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.PCT/SE 91/00557

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the Swedish Patent Office EDP file on 31/10/91
The Swedish Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A1- 0303746	89-02-22	HU-A- 44706	88-04-28